Compugen (CGEN) News Today $1.48 -0.06 (-3.59%) Closing price 03:58 PM EasternExtended Trading$1.47 -0.01 (-0.34%) As of 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CGEN Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Northern Trust Corp Raises Stock Position in Compugen Ltd. (NASDAQ:CGEN)Northern Trust Corp boosted its holdings in Compugen Ltd. (NASDAQ:CGEN - Free Report) by 936.9% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 941,825 shares of the biotechnology company's stock after buying an additional 850,997 shares duMay 29 at 3:08 AM | marketbeat.comThese Analysts Just Made An Incredible Downgrade To Their Compugen Ltd. (NASDAQ:CGEN) EPS ForecastsMay 25, 2025 | uk.finance.yahoo.comAnalysts Offer Predictions for Compugen FY2025 EarningsCompugen Ltd. (NASDAQ:CGEN - Free Report) - Stock analysts at Leerink Partnrs issued their FY2025 earnings per share estimates for Compugen in a research note issued on Monday, May 19th. Leerink Partnrs analyst D. Graybosch expects that the biotechnology company will post earnings of ($0.41) perMay 24, 2025 | marketbeat.comQ2 Earnings Estimate for Compugen Issued By Leerink PartnrsCompugen Ltd. (NASDAQ:CGEN - Free Report) - Equities research analysts at Leerink Partnrs issued their Q2 2025 earnings per share estimates for Compugen in a research report issued on Monday, May 19th. Leerink Partnrs analyst D. Graybosch expects that the biotechnology company will post earningsMay 23, 2025 | marketbeat.comWhat is Leerink Partnrs' Forecast for Compugen Q2 Earnings?May 23, 2025 | americanbankingnews.comCompugen Ltd. (CGEN) Q1 2025 Earnings Call TranscriptMay 22, 2025 | seekingalpha.comCompugen First Quarter 2025 Earnings: Misses ExpectationsMay 20, 2025 | uk.finance.yahoo.comCompugen Ltd. (NASDAQ:CGEN) Q1 2025 Earnings Call TranscriptMay 20, 2025 | insidermonkey.comCompugen Ltd. (NASDAQ:CGEN) Q1 2025 Earnings Call TranscriptMay 20, 2025 | msn.comCompugen’s Q1 2025: Clinical Progress and Financial StabilityMay 20, 2025 | tipranks.comCompugen Ltd.: Compugen Reports First Quarter 2025 ResultsMay 19, 2025 | finanznachrichten.deCompugen Reports Q1 2025 Results and Strategic DevelopmentsMay 19, 2025 | tipranks.comCompugen Reports First Quarter 2025 ResultsMay 19, 2025 | prnewswire.comUncovering Potential: Compugen's Earnings PreviewMay 16, 2025 | benzinga.comCompugen Q1 2025 Earnings PreviewMay 16, 2025 | msn.comCompugen announces executive leadership changesMay 15, 2025 | uk.investing.comCompugen Announces Leadership Transitions Effective September 2025May 13, 2025 | prnewswire.comCompugen (CGEN) Projected to Post Quarterly Earnings on MondayCompugen (NASDAQ:CGEN) will be releasing its Q1 2025 earnings before the market opens on Monday, May 19. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-19-compugen-ltd-stock/)May 13, 2025 | marketbeat.comCompugen to Release First Quarter 2025 Results on Monday, May 19, 2025May 5, 2025 | prnewswire.comCompugen to Participate in Multiple Virtual Investor Conferences in April 2025March 26, 2025 | prnewswire.comCompugen Ltd. (CGEN): Among the Penny Stocks With Huge Upside Potential According to AnalystsMarch 23, 2025 | insidermonkey.comCompugen (NASDAQ:CGEN) Cut to "Hold" at StockNews.comStockNews.com lowered shares of Compugen from a "buy" rating to a "hold" rating in a research note on Wednesday.March 6, 2025 | marketbeat.comCalculating The Intrinsic Value Of Compugen Ltd. (NASDAQ:CGEN)March 6, 2025 | uk.finance.yahoo.comCompugen Ltd. (NASDAQ:CGEN) Q4 2024 Earnings Call TranscriptMarch 5, 2025 | insidermonkey.comCompugen reports Q4 EPS (7c) vs. 11c last yearMarch 4, 2025 | markets.businessinsider.comCompugen Ltd. (CGEN) Q4 2024 Earnings Call TranscriptMarch 4, 2025 | seekingalpha.comCompugen (NASDAQ:CGEN) Issues Quarterly Earnings Results, Misses Expectations By $0.14 EPSCompugen (NASDAQ:CGEN - Get Free Report) issued its earnings results on Tuesday. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.07 by ($0.14). Compugen had a net margin of 2.67% and a return on equity of 2.62%.March 4, 2025 | marketbeat.comCompugen Reports Fourth Quarter and Full Year 2024 ResultsMarch 4, 2025 | prnewswire.comCompugen to Participate in a Fireside Chat at the 2025 Leerink Partners Global Healthcare ConferenceMarch 3, 2025 | prnewswire.comCompugen Enhances its AI/ML Predictive Computational Discovery Platform, Unigen™ with Ultima Genomics' Single Cell Genomics Sequencing TechnologyFebruary 26, 2025 | prnewswire.comCompugen (CGEN) Projected to Post Quarterly Earnings on TuesdayCompugen (NASDAQ:CGEN) will be releasing earnings before the market opens on Tuesday, March 4. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=667255)February 25, 2025 | marketbeat.comCompugen Ltd. Sets Date for Q4 2024 Financial Results AnnouncementFebruary 18, 2025 | tipranks.comCompugen: Immuno-Oncology Innovator Poised For A ComebackFebruary 18, 2025 | seekingalpha.comCompugen to Release Fourth Quarter and Full Year 2024 Financial Results on Tuesday, March 4, 2025February 18, 2025 | prnewswire.comCompugen (NASDAQ:CGEN) Shares Cross Above 200-Day Moving Average - Time to Sell?Compugen (NASDAQ:CGEN) Share Price Crosses Above 200-Day Moving Average - Here's WhyFebruary 18, 2025 | marketbeat.comCompugen Ltd. (CGEN) Stock Price, News, Quote & History - Yahoo FinanceFebruary 9, 2025 | finance.yahoo.comCompugen to Present at the Oppenheimer 35th Annual Healthcare Life Sciences ConferenceFebruary 4, 2025 | prnewswire.comJPMorgan Chase & Co. Has $122,000 Holdings in Compugen Ltd. (NASDAQ:CGEN)JPMorgan Chase & Co. trimmed its position in Compugen Ltd. (NASDAQ:CGEN - Free Report) by 62.7% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 67,485 shares of the biotechnology company's stock after selling 113,287 shaFebruary 3, 2025 | marketbeat.comCompugen Ltd. (CGEN.TA)January 30, 2025 | ca.finance.yahoo.comCompugen (NASDAQ:CGEN) Share Price Passes Above 200 Day Moving Average - Here's WhyCompugen (NASDAQ:CGEN) Shares Pass Above 200 Day Moving Average - Should You Sell?January 29, 2025 | marketbeat.comCompugen (NASDAQ:CGEN) Share Price Crosses Above Two Hundred Day Moving Average - Should You Sell?Compugen (NASDAQ:CGEN) Shares Cross Above Two Hundred Day Moving Average - Should You Sell?January 21, 2025 | marketbeat.comOppenheimer Reaffirms Their Buy Rating on Compugen (CGEN)January 14, 2025 | markets.businessinsider.comCompugen initiated with an Outperform at OppenheimerJanuary 13, 2025 | markets.businessinsider.comCompugen (NASDAQ:CGEN) Earns Outperform Rating from Analysts at OppenheimerOppenheimer began coverage on shares of Compugen in a research note on Monday. They set an "outperform" rating and a $4.00 price objective on the stock.January 13, 2025 | marketbeat.comCompugen Announces First Patient Dosed in Phase 1 Clinical Trial to Evaluate COM503 as Monotherapy and in Combination with Zimberelimab in Advanced Solid TumorsJanuary 8, 2025 | prnewswire.comCompugen Ltd.January 3, 2025 | wsj.comThe past five years for Compugen (NASDAQ:CGEN) investors has not been profitableDecember 26, 2024 | uk.finance.yahoo.comCompugen Bolsters Cancer Therapy Portfolio with New PatentNovember 28, 2024 | markets.businessinsider.comCompugen Expands its Intellectual Property Portfolio with New U.S. Patent Covering Triple Combination Use of COM902 (reduced Fc anti-TIGIT) with anti-PD-1 and anti-PVRIG AntibodiesNovember 27, 2024 | prnewswire.comRoche anti-TIGIT therapy fails to extend survival in late-stage lung cancer trialNovember 26, 2024 | msn.com Get Compugen News Delivered to You Automatically Sign up to receive the latest news and ratings for CGEN and its competitors with MarketBeat's FREE daily newsletter. Email Address CGEN Media Mentions By Week CGEN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CGEN News Sentiment▼1.210.88▲Average Medical News Sentiment CGEN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CGEN Articles This Week▼51▲CGEN Articles Average Week Get Compugen News Delivered to You Automatically Sign up to receive the latest news and ratings for CGEN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Valneva News Stoke Therapeutics News Bicara Therapeutics News Relay Therapeutics News Tyra Biosciences News Upstream Bio News Kura Oncology News REGENXBIO News Arvinas News Amylyx Pharmaceuticals News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CGEN) was last updated on 5/30/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon Set to Shock the World on June 1st?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredTrump Just Gave the Green Light to Rewrite Social Security?In a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Compugen Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Compugen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
